Imricor launches cardiovascular unit after FDA clearances for MR-guided catheters

The new business targets U.S. hospitals with radiation-free cardiac catheterization in interventional MR labs, with the company citing roughly 35% per-patient procedural time savings.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.